Figure 5.

Engineered T cells for cancer therapy. (A) T cells (blue) conjugated with nanoparticles (magenta) loaded with a chemodrug (SN-38) were used for drug delivery to lymphoma; (B) T cells with surface-bound chemodrug preferentially accumulated in tumor-bearing lymphoid tissues following systemic administration, and significantly improved the drug distribution in lymph nodes, compared with equivalent or 10-fold higher dose of the nanoparticulate or soluble drug, respectively. Reproduced with permission [124].